Top in endocrinology: Tirzepatide improves sleep apnea; updated prolactinomas guidance
Tirzepatide improved obstructive sleep apnea symptoms compared with placebo among adults with obesity, according to results from the SURMOUNT-OSA trials.After 1 year of treatment, patients receiving tirzepatide (Zepbound, Eli Lilly) had 27.4 fewer events per hour on the apnea-hypopnea index, while patients receiving placebo had 4.8 fewer events per hour. It was the top story in endocrinology